Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comparison of outcomes in pediatric patients with acute leukemia undergoing allogeneic HLA-haploidentical hematopoietic stem cell transplantation (HSCT) after in vitro a/b T- and CD19-cell depletion or In Vivo administration of post-transplant cyclophosphamide: An EBMT pediatric working party study

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMichael MaschanRRRawad RihaniIGIbrahim Ghemlas

Discussion

Loading...

Member takes

Overview

Analysis shows a/b-TCD improves leukemia-free survival in pediatric acute leukemia, suggesting benefits over PTCY.

Key Points

  • To compare outcomes of pediatric patients with acute leukemia following two HSCT platforms: a/b-TCD and PTCY.
  • Included 1071 pediatric patients with AML or ALL
  • Conducted pair-match analysis for outcome evaluation
  • Estimated impacts using Cox model with cluster effects
  • 4-yr overall survival was 55.7%, with 58.5% for a/b-TCD and 52.8% for PTCY
  • a/b-TCD patients had lower incidences of GVHD compared to PTCY
  • Cox model indicated worse leukemia-free survival and higher NRM for PTCY group

Cite This Study

Maschan et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e18fhttps://doi.org/10.1182/blood-2025-515
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy2026
  2. 2Combination of post-transplant cyclophosphamide and anti-thymocyte globulin for haploidentical stem cell transplantation in pediatric patients with acute leukemia2026
  3. 3Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT2025
  4. 4Comparison of autologous HCT versus haploidentical donor HCT for Ph+ B-ALL patients following TKI therapy. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation2025
  5. 5Post-Transplant Cyclophosphamide Allows Allogeneic Hematopoietic Stem-Cell Transplantation Across Donor Types for Nonmalignant Hematologic Diseases2026